Conversely, a subset of NSCLCs defined by KRAS/STK11 co-mutation has been found to be associated with a “cold” tumor immune microenvironment and marked resistance to anti-PD-1/PD-L1 therapy15. The gene discussed is KRAS; the disease is neoplasm.